Arzneimittelforschung 2008; 58(1): 1-10
DOI: 10.1055/s-0031-1296459
Editio Cantor Verlag Aulendorf (Germany)

Melatonergic Drugs in Clinical Practice

Rüdiger Hardeland
1   Johann Friedrich Blumenbach Institute of Zoology and Anthropology, University of Göttingen, Göttingen, Germany
Burkhard Poeggeler
1   Johann Friedrich Blumenbach Institute of Zoology and Anthropology, University of Göttingen, Göttingen, Germany
Venkataramanujan Srinivasan
2   Department of Physiology, School of Medical Sciences, University Sains Malaysia, Kubang Kerian, Kota Bharu, Kelantan, Malaysia
Ilya Trakht
3   Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA
Seithikurippu R Pandi-Perumal
3   Division of Clinical Pharmacology and Experimental Therapeutics, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY, USA
Daniel P Cardinali
4   Department of Physiology, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina
› Author Affiliations
Further Information

Publication History

Publication Date:
15 December 2011 (online)


Melatonin (CAS 73-31-4) has both hypnotic and sleep/wake rhythm regulating properties. These sleep promoting actions, which are already demonstrable in healthy humans, have been found useful in subjects suffering from circadian rhythm sleep disorders (CRSD) like delayed sleep phase syndrome (DSPS), jet lag and shift-work sleep disorder. Low nocturnal melatonin production and secretion have been documented in elderly insomniacs, and exogenous melatonin has been shown to be beneficial in treating sleep disturbances of these patients. In comparison to a number of sleep-promoting compounds that are usually prescribed, such as benzodiazepines and z-drugs (Zolpidem and Zopiclon belonging to the latter ones), melatonin has several advantages of clinical value: it does not cause hangover nor withdrawal effects and is devoid of any addictive potential. However, recent meta-analyses revealed that melatonin is not sufficiently effective in treating most primary sleep disorders. Some of the reasons for a limited efficacy of this natural hormone are related to its extremely short half-life in the circulation, and to the fact that sleep maintenance is also regulated by mechanisms downstream of primary melatonergic actions. Hence, there is an urgent need for the development of melatonin receptor agonists with a longer half-life, which could be suitable for a successful treatment of insomnia. Such requirements are fulfilled by ramelteon (CAS 196597-26-9), which possesses a high affinity for the melatonin receptors MT1 and MT2 present in the circadian pacemaker, the suprachiasmatic nucleus (SCN). Ramelteon also has a substantially longer half-life than melatonin. This new drug has been successfully used in treating elderly insomniacs without any adverse effects reported, and is promising for treating patients with primary insomnia and also those suffering from CRSD. Since sleep disturbances constitute the most prevalent symptoms of various forms of depression, the need for the development of an ideal antidepressant was felt, which would both improve sleep and mitigate depressive symptoms. Since most of the currently used antidepressants, including the selective serotonin re-uptake inhibitors worsen the sleep disturbances of depressive patients, another novel melatonergic drug, agomelatine (CAS 138112-76-2), holds some promise because of its particular combination of actions: it has a high affinity for MT1 and MT2 receptors in the SCN, but it acts additionally as a 5-HT2C antagonist [5-hydroxytryptamine (serotonin) receptor 2C antagonist]. The latter property, which is decisive for the antidepressive action, would not favor but potentially antagonize sleep, but this is overcome during night by the melatonergic, sleep-promoting effect. This drug has been found beneficial in treating patients with major depressive and seasonal affective disorders. Unlike the other antidepressants, agomelatine improves both sleep and clinical symptoms of depressive illness and does not have any of the side effects on sleep seen with other compounds in use. This property seems to be of particular value because of the aggravating effects of disturbed sleep in the development of depressive symptoms. Based on these facts, agomelatine seems to be a drug of superior efficacy with a promising future in the treatment of depressive disorders. However, long-term safety studies are required for both ramelteon and agomelatine, with a consideration of the pharmacology of their metabolites, their effects on redox metabolism, and of eventual undesired melaton-ergic effects, e. g., on reproductive functions. According to current data, both compounds seem to be safe during short-term treatment.

  • References

  • 1 Lerner AB, Case JD, Heinzelman RW. The structure of melatonin. J Am Chem Soc. 1959; 81: 6084-6085
  • 2 Hardeland R, Fuhrberg B. Ubiquitous melatonin – Presence and effects in unicells, plants and animals. Trends Comp Biochem Physiol. 1996; 2: 25-45
  • 3 Tan D-X, Manchester LC, Hardeland R, Lopez-Burillo S, Mayo JC, Sainz RM et al. Melatonin – a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res. 2003; 34: 75-78
  • 4 Hardeland R, Pandi-Perumal SR. Melatonin, a potent agent in antioxidative defense: Actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond). 2005; 2 (article no. 22) [DOI 10.1186/1743-7075-2-22]
  • 5 Pandi-Perumal SR, Srinivasan V, Maestroni GJM, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature’s most versatile biological signal?. FEBS J. 2006; 273: 2813-2838
  • 6 Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D et al. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer’s disease. J Neurochem. 2003; 85: 1101-1108
  • 7 Fischer TW, Sweatman TW, Semak I, Sayre RM, Wortsman J, Slominski A. Constitutive and UV-induced metabolism of melatonin in keratinocytes and cell-free systems. FASEB J. 2006; 20: 1564-1566
  • 8 Reiter RJ. The melatonin rhythm: both a clock and a calendar. Experientia. 1993; 49: 654-664
  • 9 Tricoire H, Locatelli A, Chemineau P, Malpaux B. Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology. 2002; 143: 84-90
  • 10 Hardeland R, Pandi-Perumal SR, Cardinali DP. Molecules in focus – Melatonin. Int J Biochem Cell Biol. 2005; 38: 313-316
  • 11 Foster RG, Hankins M, Lucas RJ, Jenkins A, Munoz M, Thompson S et al. Non-rod, non-cone photoreception in rodents and teleost fish. Novartis Found Symp. 2003; 253: 3-23
  • 12 Foster RG. Seeing the light … in a new way. J Neuroendocrinol. 2004; 16: 179-180
  • 13 Dkhissi-Benyahya O, Gronfier C, De Vanssay W, Flamant F, Cooper HM. Modeling the role of mid-wavelength cones in circadian responses to light. Neuron. 2007; 53: 677-687
  • 14 Moore RY. Neural control of the pineal gland. Behav Brain Res. 1996; 73: 125-130
  • 15 Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature. 2005; 437: 1257-1263
  • 16 Dijk DJ, Cajochen C. Melatonin and the circadian regulation of sleep initiation, consolidation, structure and the sleep EEG. J Biol Rhythms. 1997; 12: 627-635
  • 17 Krauchi K, Wirz-Justice A. Circadian clues to sleep onset mechanisms. Neuropsychopharmacology. 2001; 25: S92-S96
  • 18 Gauer F, Masson-Pévet M, Stehle J, Pévet P. Daily variations in melatonin receptor density of rat pars tuberalis and suprachiasmatic nuclei are distinctly regulated. Brain Res. 1994; 641: 92-98
  • 19 Pévet P, Bothorel B, Slotten H, Saboureau M. The chrono-biotic properties of melatonin. Cell Tissue Res. 2002; 309: 183-191
  • 20 Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML. Activation of MT2 melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol. 2001; 280: C110-C118
  • 21 Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005; 27: 101-110
  • 22 Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic clock. Neuron. 1997; 19: 91-102
  • 23 Jin X, von Gall C, Pieschl RL, Gribkoff VK, Stehle JH, Reppert SM et al. Targeted disruption of the mouse Mel1b melatonin receptor. Mol Cell Biol. 2003; 23: 1054-1060
  • 24 von CGall, Stehle JH, Weaver DR. Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res. 2002; 309: 151-162
  • 25 Hardeland R. Antioxidative protection by melatonin -Multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine. 2005; 27: 119-130
  • 26 Zhdanova IV, Wurtman RJ, Lynch HJ, Ives JR, Dollins AB, Morabito C et al. Sleep inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther. 1995; 57: 552-558
  • 27 Zhdanova IV, Wurtman RJ, Morabito C, Piotrovska VR, Lynch HJ. Effects of low oral doses of melatonin, given 2–4h before habitual bedtime, on sleep in normal young humans. Sleep. 1996; 19: 423-131
  • 28 Mendelson WB. Efficacy of melatonin as a hypnotic agent. J Biol Rhythms. 1997; 12: 651-656
  • 29 Mendelson WB. A critical evaluation of the hypnotic efficacy of melatonin. Sleep. 1997; 20: 916-919
  • 30 Buscemi N, Van der meer B, Hooton N, Pandya R, Tjosvold L, Hartling L et al. The efficacy and safety of exogenous melatonin for primary sleep disorders: A meta-analysis. J Gen Intern Med. 2005; 20: 1151-1158
  • 31 Buscemi N, Van der meer B, Hooton N, Pandya R, Tjosvoid L, Hartling L et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders accompanying sleep restriction. BMJ. 2006; 332: 385-393
  • 32 Gorfine T, Assaf Y, Goshen-Gottstein Y, Zisapel N. Sleep-anticipating effects of melatonin in the human brain. Neuroimage. 2006; 31: 410-418
  • 33 Dalton EJ, Rotondi D, Levitan RD, Kennedy SH, Brown GM. Use of slow-release melatonin in treatment-resistant depression. J Psychiatry Neurosci. 2000; 25: 48-52
  • 34 Leger D, Laudon M, Zisapel N. Nocturnal 6-sulfatoxymelatonin excretion in insomnia and its relationship to the response to melatonin replacement therapy. Am J Med. 2004; 116: 91-9s5
  • 35 Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ, Deng MH. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci USA. 1994; 91: 1824-1828
  • 36 Garfinkel D, Laudon M, Nof D, Zisapel N. Improvement of sleep quality in elderly people by controlled release melatonin. Lancet. 1995; 346: 541-544
  • 37 Haimov I, Lavie P, Laudon M, Herer P, Vigder C, Zisapel N. Melatonin replacement therapy of elderly insomniacs. Sleep. 1995; 18: 598-603
  • 38 Monti JM, Alvarino F, Cardinali DP, Savio I, Pintos A. Polysomnographic study of the effects of melatonin on sleep in elderly patients with chronic primary insomnia. Arch Gerontol Geriar. 1999; 28: 85-98
  • 39 Zhdanova IV, Wurtman RJ, Regan MM, Taylor J, Shi JP, Le-clair OU. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab. 2001; 86: 4727-4730
  • 40 Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev. 2005; 9: 25-39
  • 41 Arendt J, Skene DJ, Middeleton B, Lockley SW, Deacon S. Efficacy of melatonin treatment in jet lag, shift work, and blindness. J Biol Rhythms. 1997; 12: 604-617
  • 42 Lewy AJ, Sack RL. Exogenous melatonin’s phase-shifting effects on the endogenous melatonin profile in sighted humans: a brief review and critique of the literature. J Biol Rhythms. 1997; 12: 588-594
  • 43 Cardinali DP, Brusco LI, Lloret SP, Furio AM. Melatonin in sleep disorders and jet lag. Neuroendocrinal Lett. 2002; 23 (Suppl 1) 9-13
  • 44 Cardinali DP, Furio AM, Reyes MP, Brusco LI. The use of chronobiotics in the resynchronization of the sleep-wake cycle. Cancer Causes Control. 2006; 17: 601-609
  • 45 Srinivasan V, Smits MG, Kayumov L, Pandi-Perumal SR, Cardinali DP, Thorpy MJ. Melatonin in circadian rhythm sleep disorders. In: Cardinali DP, Pandi-Perumal SR, eds Neuroendocrine Correlates of Sleep/Wakefulness. New York: Springer; 2006. p. 269-294
  • 46 Hack LM, Lockley SW, Arendt J, Skene DJ. The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects. J Biol Rhythms. 2003; 18: 420-429
  • 47 Skene DJ, Arendt J. Circadian rhythm sleep disorders in the blind and their treatment with melatonin. Sleep Med. 2007; 8: 651-655
  • 48 Turek FW, Gillette MU. Melatonin, sleep, and circadian rhythms: rationale for development of specific melatonin agonists. Sleep Med. 2004; 5: 523-532
  • 49 Miyamoto M, Nishikawa H, Ohta H, Uchikawa O, Ohkawa O, Ohkawa S. Behavioural pharmacology of TAK-375 in small animals. Ann Neurol. 2003; 54: S46
  • 50 Kato K, Hirai K, Nishiyama K, Uchikawa O, Fukatsu K, Ohkawa S et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005; 48: 301-310
  • 51 McGechan A, Wellington K. Ramelteon. CNS Drugs. 2005; 19: 1057-1065
  • 52 Macías M, Escames G, Leon J, Coto A, Sbihi Y, Osuna A et al. Calreticulin — melatonin. An unexpected relationship. Eur J Biochem. 2003; 270: 832-40
  • 53 Carlberg C. Gene regulation by melatonin. Ann NY Acad Sci. 2000; 917: 387-396
  • 54 Karim A, Tolbert D, Cao C. Disposition kinetics and tolerance of escalating single doses of ramelteon, a high affinity MT1 and MT2 melatonin receptor agonist indicated for the treatment of insomnia. J Clin Pharmacol. 2006; 46: 140-148
  • 55 Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev. 2005; 9: 11-24
  • 56 Huether G, Messner M, Rodenbeck A, Hardeland R. Effect of continuous melatonin infusions on steady-state plasma melatonin levels in rats under near physiological conditions. J Pineal Res. 1998; 24: 146-151
  • 57 Yukuhiro N, Kimura H, Nishikawa H, Ohkawa S, Yoshikubo S, Miyamoto M. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res. 2004; 1027: 59-66
  • 58 France CR, Weltman RH, Koek W, Cruz CM, McMohan LR. Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatto): dependence liability studies. Behav Neurosci. 2006; 120: 535-541
  • 59 Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug insight: the use of melatonergic agonists for the treatment of insomnia –focus on ramelteon. Nat Clin Pract Neurol. 2007; 3: 221-228
  • 60 Roth T, Seiden D, Sainati S, Wang-Weigand S, Zhang I, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med. 2006; 7: 312-318
  • 61 Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study on ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin. 2007; 23: 1005-1014
  • 62 Zammit G, Erman M, Wang-Weigand S, Sainati S, Zhang I, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects wth chronic insomnia. J Clin Sleep Med. 2007; 3: 495-504
  • 63 Kryger M, Wang-Weigand S, Roth T. Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea. Sleep Breath. 2007; 11: 159-164
  • 64 Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med. 2006; 7: 17-24
  • 65 Zee PC, Manthena P. The brain’s master circadian clock: implications and opportunities for therapy of sleep disorders. Sleep Med Rev. 2007; 11: 59-70
  • 66 Kupfer J, Thase ME. The use of the sleep laboratory in the diagnosis of affective disorders. Psychiatr Clin North Am. 1983; 6: 3-25
  • 67 Riemann D, Berger M, Voderholzer U. Sleep and depression –results from psycho-biological studies: an overview. Biol Psychol. 2001; 57: 67-103
  • 68 Lam RW. Sleep disturbances and depression. A challenge for antidepressants. Int Clin Psychopharmacol. 2006; 21: S25-S29
  • 69 Armitage R. Sleep and circadian rhythms in mood disorders. Acta Psychiatr Scand. 2007; 115 (Suppl 433) 104-115
  • 70 Srinivasan V, Smits M, Spence W, Lowe AD, Kayumov L, Pandi-Perumal SR et al. Melatonin in mood disorders. World J Psychiatry. 2006; 7: 138-151
  • 71 Venkobarao A, Parvathi devi S, Srinivasan V. Urinary melatonin in depression. Indian J Psychiatry. 1983; 25: 165-172
  • 72 Thompson C, Mezey G, Corn T, Franey C, English J, Arendt J et al. The effect of desipramine upon melatonin and cortisol secretion in depressed and normal subjects. Br J Psychiatry. 1985; 147: 389-393
  • 73 Golden RN, Markey SP, Risby ED, Rudorfer MV, Cowdry RW, Potter WZ. Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output. Arch Gen Psychiatry. 1988; 45: 150-154
  • 74 Lewy AJ, Lefler BJ, Emens JS, Bauer VK. The circadian basis of winter depression. Proc Natl Acad Sci USA. 2006; 103: 7414-7419
  • 75 Kupfer DJ. Depression and associated sleep disturbances: patient benefits with agomelatine. Eur Neuropsychopharmacol. 2006; 16: S639-S643
  • 76 Bourin M, Mocaër E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci. 2004; 29: 126-133
  • 77 Chagraoui A, Protais P, Filloux T, Mocaër E. Agomelatine (S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats. Psychopharmacology (Berl). 2003; 170: 17-22
  • 78 Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tan-credi A, Pasteau V et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003; 306: 954-964
  • 79 Rouillon F. Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol. 2006; 2: S31-S35
  • 80 Leproult R, Van Onderbergen A, L’Hermite-Baleriaux M, Van Cauter E, Copinschi G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf). 2005; 63: 298-304
  • 81 Pjrek E, Winkler D. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology. 2007; 190: 575-579
  • 82 Pandi-Perumal SR, Srinivasan V, Cardinali DP, Monti JM. Could agomelatine be the ideal antidepressant?. Expert Rev Neurotherapeutics. 2006; 6: 1595-1608
  • 83 Lôo H, Hale A, D’Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and the selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol. 2002; 17: 239-247
  • 84 Kennedy SH, Emsley R. Placebo controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006; 16: 93-100
  • 85 Olié JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007; 10: 661-673
  • 86 Guilleminault C. Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder. Eur Neuropsychopharmacol. 2005; 15: S419-S420
  • 87 Zupancic M, Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs. 2006; 20: 981-9s92
  • 88 Salva MA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C et al. Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol. 2007; 10: 691-696
  • 89 Den Boer JA, Bosker FJ, Meesters Y. Clinical efficacy of agomelatine in depression: the evidence. Int Clin Psychopharmacol. 2006; 21: S21-S24
  • 90 Banasr M, Soumier A, Hery M, Mocaer E, Daszuta A. Agomelatine, a new antidepressant induces regional changes in hippocampal neurogenesis. Biol Psychiatry. 2006; 59: 1087-1096
  • 91 Regrigny O, Delagrange P, Scalbert E, Atkinson J, Lartaud-Idjouadiene I. Melatonin improves cerebral circulation security margin in rats. Am J Physiol. 1998; 275: H139-H144
  • 92 Luboshitzky R, Shen-Orr Z, Nave R, Lavi S, Lavie P. Melatonin administration alters semen quality in healthy men. J Androl. 2002; 23: 572-578
  • 93 Silman RE, Leone RM, Hooper RJ, Preece MA. Melatonin, the pineal gland and human puberty. Nature. 1979; 282: 301-303
  • 94 Luboshitzky R, Herer P, Shen-Orr Z. Urinary 6-sulfatoxymelatonin excretion in hyperandrogenic women: the effect of cyproterone acetate-ethinyl estradiol treatment. Exp Clin Endocrinol Diabetes. 2004; 112: 102-107
  • 95 Cajochen C. TAK-375 Takeda. Curr Opin Investig Drugs. 2005; 6: 114-121
  • 96 Bogaards JJ, Hissink EM, Briggs M, Weaver R, Jochemsen R, Jackson P et al. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur J Pharm Sci. 2000; 12: 117-24